Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

被引：0
|
作者：
Leal, T. [1 ]
Wakelee, H. [2 ]
Reckamp, K. L. [3 ]
Chiappori, A. [4 ]
Oxnard, G. R. [5 ]
Waqar, S. N. [6 ]
Patel, S. P. [7 ]
Blumenschein, G. R. [8 ]
Neal, J. W. [2 ]
Harrow, K. [9 ]
Holzhausen, A. [9 ]
Selvaggi, G. [9 ]
Zhou, J. [9 ]
Horn, L. [10 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[2] Stanford Univ & Canc Inst, Stanford, CA USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Xcovery Holdings Inc, Palm Beach Gardens, FL USA
[10] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
ALK; NSCLC; ensartinib; CNS;
D O I：
10.1016/j.jtho.2019.09.131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD2.04
引用
收藏
页码：S1171 / S1172
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive stage IV non-small cell lung cancer.
    Din, Ahmed M. Mohi Ei.
    Rasmy, Ayman Ahamd
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
    Singh, Abhay
    Chen, Hongbin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6615 - 6628
  • [43] Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors
    Kim, D.
    Lee, J. K.
    Park, H. S.
    Kulig, K.
    Kim, T. M.
    Lee, S.
    Jeon, Y.
    Chung, D. H.
    Heo, D. S.
    Kim, W. H.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)
    Crino, L.
    Ahn, M-J.
    Han, J-Y.
    Liu, X.
    Ou, S-H. I.
    Shaw, A. T.
    Yang, P-C.
    Shi, Y-K.
    Lanzalone, S.
    Polli, A.
    Wilner, K. D.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer
    Hou, Donghui
    Zheng, Xiaomin
    Song, Wei
    Liu, Xiaoqing
    Wang, Sicong
    Zhou, Lina
    Tao, Xiuli
    Lv, Lv
    Sun, Qi
    Jin, Yujing
    Zhang, Zewei
    Ding, Lieming
    Wu, Ning
    Zhao, Shijun
    THORACIC CANCER, 2021, 12 (17) : 2388 - 2399
  • [46] Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study
    Martin, Claudio
    Malcervelli, Gabriela Ileana
    Martinengo, Gaston Lucas
    Levit, Patricio
    Servienti, Patricio
    Malaver, Elisa
    Brion, Laura
    Patronella, Vanesa
    Zumarraga, Andrea
    Zarba, Jose
    DRUGS-REAL WORLD OUTCOMES, 2025,
  • [47] Efficacy of DNA Vaccination Against Anaplastic Lymphoma Kinase (ALK) in Non Small Cell Lung Carcinoma (NSCLC)
    Voena, C.
    Mastini, C.
    Menotti, M.
    Di Giacomo, F.
    Longo, D. L.
    Martinengo, C.
    Aime, S.
    Inghirami, G.
    Chiarle, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S99 - S99
  • [48] Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases
    Ou, S-H. I.
    Tiseo, M.
    Camidge, R.
    Ahn, M-J.
    Huber, R. M.
    Hochmair, M. J.
    Kim, S-W.
    West, H. L.
    Reckamp, K. L.
    Molina, J. R.
    Liu, G.
    Delmonte, A.
    Viteri, S.
    Bearz, A.
    Summers, Y.
    Reichmann, W.
    Kerstein, D.
    Gettinger, S. N.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
    Qian, Jialin
    Chu, Tianqing
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2025, 17
  • [50] Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
    Park, Heae Surng
    Lee, June Koo
    Kim, Dong-Wan
    Kulig, Kimary
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    LUNG CANCER, 2012, 77 (02) : 288 - 292
12345